FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "EvidenceVariable",
  "id": "267228",
  "meta": {
    "versionId": "9",
    "lastUpdated": "2025-12-11T20:35:21.032Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
    ]
  },
  "language": "en",
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "contained": [
    {
      "resourceType": "Group",
      "id": "variable-definition",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
        ]
      },
      "membership": "conceptual",
      "characteristic": [
        {
          "code": {
            "text": "defined by CodeableConcept"
          },
          "valueCodeableConcept": {
            "text": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM"
          },
          "exclude": false,
          "timing": [
            {
              "text": "Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration"
            }
          ]
        }
      ]
    }
  ],
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-variable-handling-not-specified",
            "display": "Evidence variable handling not specified"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/EvidenceVariable/267228",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "267228",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "FEvIR Linking Identifier"
      },
      "system": "https://fevir.net/FLI",
      "value": "NCT03421379-secondaryOutcome-1",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "name": "PD_Time_to_Maximal_Concentration_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379",
  "title": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)",
  "citeAs": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267228. Revised 2025-12-11. Available at: https://fevir.net/resources/EvidenceVariable/267228. Computable resource at: https://fevir.net/resources/EvidenceVariable/267228#json.",
  "status": "active",
  "author": [
    {
      "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description": "PD assessment measured the time to maximal concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM.",
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "definition": {
    "reference": {
      "reference": "#variable-definition",
      "type": "Group"
    }
  },
  "handling": "extension"
}